When ought to six medicine depend as one?
That query is on the coronary heart of an uncommon problem that the pharma firm Novo Nordisk is pursuing towards the federal authorities. And the reply might have main ramifications for the Medicare drug worth negotiation program, a signature accomplishment of former President Biden that President Trump has additionally embraced.
Novo argues that the federal authorities needs to be pressured to barter the worth for six of its insulin merchandise individually, though all of them comprise the identical energetic ingredient. The federal government says that the regulation permits it to lump all these merchandise collectively.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
